Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | CASP2 | P42575 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SELP | P16109 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10171436 | 1.00 | FAAH (0.48) | FAAHDNM1CASP2EPHX2SLC6A5 | |
| SCHEMBL16327170 | 1.00 | FAAH (0.48) | FAAHDNM1CASP2EPHX2SLC6A5 | |
| SCHEMBL12334401 | 0.96 | CASP2 (0.48) | FAAHDNM1CASP2EPHX2SLC6A5 | |
| SCHEMBL765877 | 0.96 | CASP2 (0.48) | FAAHDNM1CASP2EPHX2SLC6A5 | |
| SCHEMBL10170582 | 0.94 | FAAH (0.47) | FAAHDNM1CASP2EPHX2SLC6A5 | |
| SCHEMBL10170351 | 0.94 | FAAH (0.47) | FAAHDNM1CASP2EPHX2SLC6A5 | |
| SCHEMBL16076986 | 0.88 | TSHR (0.56) | FAAHDNM1CASP2EPHX2NAAA | |
| SCHEMBL16076988 | 0.88 | TSHR (0.56) | FAAHDNM1CASP2EPHX2NAAA | |
| SCHEMBL10170355 | 0.87 | CASP2 (0.43) | FAAHDNM1CASP2EPHX2SLC6A5 | |
| SCHEMBL765576 | 0.86 | FAAH (0.62) | FAAHDNM1CASP2EPHX2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2842576-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | disclosed |
| EP-2842576-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2015-03-04 | — | — | EP | disclosed |
| EP-2033662-B1 | Transglutaminase mediated conjugation of peptides | NOVO NORDISK HEALTHCARE AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| EP-1708755-B1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK HEALTHCARE AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| EP-2368579-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2011-09-28 | — | — | EP | disclosed |
| EP-2033662-A1 | Transglutaminase mediated conjugation of peptides | Novo Nordisk Health Care AG (CH) | 2009-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | TGM2, TGM3, TGM1 | FAAH 2760/4885DNM1 2688/4885CASP2 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.